Overview

Rheumatoid Arthritis Drugs Market is estimated to value over CAGR of over 4.3% during the forecast period 2022 to 2028.

FutureWise Market Research has offered an in-depth analysis on the Rheumatoid Arthritis Drugs Market. It provides a detailed synopsis of rheumatoid arthritis drugs market trends affecting the market growth. Additionally, this report offers region-wise proliferation and the graph of profitability, instrumental information pertaining to the rheumatoid arthritis drugs market share and SWOT analysis of this market. Moreover, this report provides the current market position of key market players in the competitive analysis of rheumatoid arthritis drugs market, while inflating their corporate strategies and provision of products.

The rheumatoid arthritis drugs market is predicted to achieve a substantial growth rate over the forecast timeframe as per the research study. The report further illustrates that this business is anticipated to register significant market numbers during the forecast period. Furthermore, this report offers key insights regarding the current overall industry valuation and it mentions the segmentation of the rheumatoid arthritis drugs market coupled with the profitable opportunities for the growth across this business vertical.

Key market players included in the rheumatoid arthritis drugs industry are Abbvie, Biogen Inc., Bristol-Myers Squibb, Celgene Corp., Celltrion Inc., Johnson & Johnson, Medimmune LLC, Merck & Co. Inc., Novartis International AG, Takeda Pharmaceutical Co. Ltd.

Rheumatoid Arthritis Drugs Market Segmentation:
By Therapeutic Molecule
• Pharmaceuticals
  o NSAIDs
  o Analgesics
  o DMARDs
  o Corticosteroids
• Biopharmaceuticals
  o Biologics
  o Biosimilars

By Route of Administration

• Oral 
• Parenteral

By Sales Channel

• Prescription 
• Over-the-counter (OTC)

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the rheumatoid arthritis drugs market by therapeutic molecule, by route of administration, by sales channel and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
• To forecast and evaluate micro-markets and the overall market 
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
• To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
           1.1. Objectives of the Study 
           1.2. Market Definition 
           1.3. Market Scope 
                   1.3.1. Years Considered for the Study
                   1.3.2. Market Covered
           1.4. Currency 
           1.5. Limitations 
           1.6. Stakeholders 
 2.  Research Methodology 
           2.1. Research Data 
                   2.1.1. Secondary Data
                           2.1.1.1. Key Data from Secondary Sources
                   2.1.2. Primary Data
                            2.1.2.1. Key Data from Primary Sources
           2.2. Market Size Estimation 
           2.3. Market Breakdown and Data Triangulation 
           2.4. Assumptions for the Study  
3. Executive Summary
           3.1. Market Outlook
           3.2. Segment Outlook
           3.3. Competitive Insights
4. Global Rheumatoid Arthritis Drugs Market Variables, Trends & Scope
           4.1. Market Lineage Outlook
           4.2. Penetration and Growth Prospect Mapping
           4.3. Industry Value Chain Analysis
           4.4. Cost Analysis Breakdown
           4.5. Technology Overview
           4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances
5. Global Rheumatoid Arthritis Drugs Market Overview
           5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                             5.1.1.1. Increasing focus of Rheumatoid Arthritis Drugs Companies on Brand Protection
                             5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                             5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                             5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Rheumatoid Arthritis Drugs Market Analysis Tools
           6.1. Industry Analysis - Porter’s
                   6.1.1. Supplier Power
                   6.1.2. Buyer Power
                   6.1.3. Substitution Threat
                   6.1.4. Threat from New Entrants
                   6.1.5. Competitive Rivalry
           6.2. Pestel Analysis
                   6.2.1. Political Landscape
                   6.2.2. Environmental Landscape
                   6.2.3. Social Landscape
                   6.2.4. Technology Landscape
                   6.2.5. Legal Landscape
           6.3. Major Deals And Strategic Alliances Analysis
                   6.3.1. Joint Ventures
                   6.3.2. Mergers and Acquisitions
                   6.3.3. Licensing and Partnership
                   6.3.4. Technology Collaborations
                   6.3.5. Strategic Divestments
           6.4. Market Entry Strategies
           6.5. Case Studies
7. Global Rheumatoid Arthritis Drugs Market, By Therapeutic Molecule Historical Analysis and Forecast 2022-2028 (USD Million)
           7.1. Pharmaceuticals
                7.1.1. NSAIDs
                7.1.2. Analgesics
                7.1.3. DMARDs
                7.1.4. Corticosteroids
           7.2. Biopharmaceuticals
                7.2.1. Biologics
                7.2.2. Biosimilars
8. Global Rheumatoid Arthritis Drugs Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million)
           8.1. Oral 
           8.2. Parenteral
9. Global Rheumatoid Arthritis Drugs Market, By Sales Channel Historical Analysis and Forecast 2022-2028 (USD Million)
           9.1. Prescription     
           9.2. Over-the-counter (OTC)
10. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
           10.1. Introduction
           10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
                     10.2.1. U.S.A
                     10.2.2. Canada
                     10.2.3. Mexico
           10.3. Market Size (USD Million) Forecast for North America 2022-2028 
11. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
           11.1. Introduction
           11.2. Regional Market Trends
           11.3. Historical Market Size (USD Million) Analysis By Country, 2016-2020
                     11.3.1. Brazil
                     11.3.2. Venezuela
                     11.3.3. Argentina
                     11.3.4. Rest of Latin America
           11.4. Market Size (USD Million) Forecast for Latin America 2022-2028  
12. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
           12.1. Introduction
           12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
                     12.2.1. Germany
                     12.2.2. U.K
                     12.2.3. France
                     12.2.4. Italy
                     12.2.5. Spain
                     12.2.6. Russia
                     12.2.7. Poland
                     12.2.8. Switzerland
                     12.2.9. Rest of Western Europe
           12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
           13.1. Introduction
           13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
                     13.2.1. Japan
                     13.2.2. China
                     13.2.3. Singapore
                     13.2.4. India
                     13.2.5. Australia and New Zealand
                     13.2.6. ASEAN
                     13.2.7. South Korea
                     13.2.8. Taiwan
                     13.2.9. Rest of Asia Pacific
           13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
           14.1. Introduction
           14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
                     14.2.1. GCC
                     14.2.2. Israel
                     14.2.3. South Africa
                     14.2.4. Rest of MEA
           14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
           15.1. Abbvie
                     15.1.1. Company Overview
                     15.1.2. Product Portfolio
                     15.1.3. SWOT Analysis
                     15.1.4. Financial Overview
                     15.1.5. Strategic Overview
           15.2. Biogen Inc.
                     15.2.1. Company Overview
                     15.2.2. Product Portfolio
                     15.2.3. SWOT Analysis
                     15.2.4. Financial Overview
                     15.2.5. Strategic Overview
           15.3. Bristol-Myers Squibb
                     15.3.1. Company Overview
                     15.3.2. Product Portfolio
                     15.3.3. SWOT Analysis
                     15.3.4. Financial Overview
                     15.3.5. Strategic Overview
           15.4. Celgene Corp.
                     15.4.1. Company Overview
                     15.4.2. Product Portfolio
                     15.4.3. SWOT Analysis
                     15.4.4. Financial Overview
                     15.4.5. Strategic Overview
           15.5   Celltrion Inc.
                     15.5.1. Company Overview
                     15.5.2. Product Portfolio
                     15.5.3. SWOT Analysis
                     15.5.4. Financial Overview
                     15.5.5. Strategic Overview
           15.6 Johnson & Johnson
                     15.6.1. Company Overview
                     15.6.2. Product Portfolio
                     15.6.3. SWOT Analysis
                     15.6.4. Financial Overview
                     15.6.5. Strategic Overview
           15.7. Medimmune LLC
                     15.7.1. Company Overview
                     15.7.2. Product Portfolio
                     15.7.3. SWOT Analysis
                     15.7.4. Financial Overview
                     15.7.5. Strategic Overview
           15.8. Merck & Co. Inc.
                     15.8.1. Company Overview
                     15.8.2. Product Portfolio
                     15.8.3. SWOT Analysis
                     15.8.4. Financial Overview
                     15.8.5. Strategic Overview
           15.9. Novartis International AG
                     15.9.1. Company Overview
                     15.9.2. Product Portfolio
                     15.9.3. SWOT Analysis
                     15.9.4. Financial Overview
                     15.9.5. Strategic Overview
           15.10. Takeda Pharmaceutical Co. Ltd
                     15.10.1. Company Overview
                     15.10.2. Product Portfolio
                     15.10.3. SWOT Analysis
                     15.10.4. Financial Overview
                     15.10.5. Strategic Overview
16. Pre and Post COVID-19 Impact
    16.1. Positive influence on the healthcare industry
    16.2. The financial disruption of the manufacturing sector
    16.3. Impact of COVID-19 on emerging companies
    16.4. Significant mandates in the healthcare regulations initiated by administrations
    16.5. The overall economic slowdown of the developing and developed nations
17. FutureWise SME Key Takeaway Points for Client

Tables

Figures